Preparation of Targeted Drug-Loaded Nanobubbles and Its Effect in Improvement of Renal Function in Patients with Hyperuricemia

The effects of targeted drug-loaded nanobubble (DLNB) on the treatment of patients with hyperuricemia (HUA) and the improvement of renal function were explored by constructing targeted DLNB. G250 targeted allopurinol-loaded NB (ANBs) was prepared by filming-rehydration method and its physicochemical properties were investigated. A total of 80 patients with HUA admitted to the hospital from July 2017 to July 2019 were selected and divided into control group and experimental group, with 40 patients in each group, treated for 4 weeks. Blood UA (UA), total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), alanine transaminase (ALT), aspartate transaminase (AST), blood urea nitrogen (BUN), blood creatinine (Cr) and other related indicators were compared before and after treatment. Targeted ANBs was successfully constructed and its targeting in vitro was guaranteed. The effective rate of control group was 65.00%, and that of experimental group was 77.50%, with evident difference (P < 0.05). In contrast to control group, UA, TC, TG, HDL, and LDL were notably decreased in the experimental group after treatment, and the difference was evident (P < 0.05). ALT, AST, BU, and Cr also showed notable improvement (P < 0.05). Targeted ANBs had good therapeutic effect on patients with HUA, and it also played a certain role in improving liver function and kidney function in HUA patients.